Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q37188715)
Watch
English
A review of phase II trial designs for initial marker validation.
scientific article published on 08 May 2013
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
title
A review of phase II trial designs for initial marker validation
(English)
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
main subject
phase II clinical trial
0 references
author
Daniel J. Sargent
series ordinal
3
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
author name string
Sumithra J Mandrekar
series ordinal
1
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
Ming-Wen An
series ordinal
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
language of work or name
English
0 references
publication date
8 May 2013
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
published in
Contemporary Clinical Trials
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
volume
36
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
issue
2
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
page(s)
597-604
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
cites work
Randomized phase II trial designs with biomarkers
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
A 2-stage phase II design with direct assignment option in stage II for initial marker validation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
The BATTLE trial: personalizing therapy for lung cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Design of clinical trials for biomarker research in oncology
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
All-comers versus enrichment design strategy in phase II trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Outcome--adaptive randomization: is it useful?
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Biomarkers and surrogate end points--the challenge of statistical validation
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Effective incorporation of biomarkers into phase II trials
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Biomarkers and surrogate endpoints: preferred definitions and conceptual framework
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Interim analyses for randomized clinical trials: the group sequential approach
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
6 September 2017
Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
26 June 2018
Designs for group sequential phase II clinical trials.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
26 June 2018
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
3 September 2018
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset
1 reference
stated in
PubMed Central
reference URL
https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3779487
retrieved
20 October 2018
An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23665336
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Adaptive clinical trials: the promise and the caution
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23665336
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Limitations of adaptive clinical trials
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23665336
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Evaluating the efficiency of targeted designs for randomized clinical trials
1 reference
stated in
PubMed
reference URL
https://pubmed.ncbi.nlm.nih.gov/23665336
retrieved
12 December 2020
based on heuristic
inferred from PubMed ID database lookup
Identifiers
DOI
10.1016/J.CCT.2013.05.001
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
PMC publication ID
3779487
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
PubMed publication ID
23665336
1 reference
stated in
Europe PubMed Central
PMC publication ID
3779487
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23665336%20AND%20SRC:MED&resulttype=core&format=json
retrieved
1 March 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
